Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Australia slashes prescription prices across therapeutic areas

The Australian government is reducing the price of 1,100 medicine brands listed on the Pharmaceutical Benefits Scheme. As a result, the price paid by millions of Australians for prescription medicines will be reduced, from the start of April.

Medications for conditions including high cholesterol, Parkinson’s disease, depression, breast cancer, eczema and psoriasis are on the list of subsidized therapies.

Records show that the government spent over A$10 billion ($7.65 billion) on the scheme in the 12 months to June 2016.

The three drugs with the highest cost to government were Harvoni (ledipasvir and sofosbuvir), at a cost of A$358 million, Humira (adalimumab), costing A$335 million, and Lucentis (ranibizumab), which cost A$217.8 million.

These savings are part of more than A$20 billion ($15 billion) in savings estimated to be achieved by 2019-20, since the Australian government began reforming the Pharmaceutical Benefits Scheme in 2007.

The government has also announced a number of new treatments and indications that will be added to the list, including Adcetris (brentuximab vedotin) for Hodgkin lymphoma and Enstilar (calcipotriol and betamethasone dipropionate) for psoriasis.


Source: https://www.thepharmaletter.com/

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies